Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 8Other solid neoplasm 3Thoracic 2Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Neoplasms 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Rifampin × Thoracic × Clear all
NCT04537715 2025-02-19

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Ipsen

Phase 1 Completed
42 enrolled 39 charts
LymphoidOther hematologic neoplasmOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse, Rhabdoid Tumor, Hematologic Neoplasms

NCT02197247 2021-07-12

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

AstraZeneca

Phase 1 Completed
41 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡